Renal Denervation Devices Market By Technology (Radiofrequency-Based Renal Denervation, Ultrasound-Based Renal Denervation, Chemical-Based Renal Denervation); By Product (Renal Denervation Catheters, Energy Generators and Consoles, Accessories and Consumables); By End User (Hospitals, Ambulatory Surgical Centers, Specialty Cardiology and Hypertension Clinics); By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Renal Denervation Devices Market: Reimbursement and Specialist Referral Pathways Now Determine Commercial Scale

The Global Renal Denervation Devices Market was valued at an estimated USD 0.58 billion in 2025 and is projected to reach USD 1.54 billion by 2032, expanding at a CAGR of 15.0% during 2026–2032.

 

Renal denervation devices are minimally invasive catheter-based systems that lower blood pressure by disrupting sympathetic nerves around the renal arteries. Commercial platforms use radiofrequency or ultrasound energy, while newer investigational approaches are exploring chemical, alcohol-based denervation. With FDA-approved systems from Medtronic and ReCor Medical now available in the United States, the market focus has shifted from clinical validation to patient selection, specialist referrals, reimbursement, physician training, and treatment delivery through qualified centers.

 

The United States became the first major market to approve two renal denervation systems in November 2023, with FDA authorization for ReCor Medical’s Paradise ultrasound system and Medtronic’s Symplicity Spyral radiofrequency system. This is commercially significant given the large hypertension burden, with about 120 million U.S. adults and over 1.28 billion globally affected. To date, more than 30,000–35,000 patients worldwide have undergone renal denervation, mainly in Europe, Australia, and parts of Asia, while only several thousand procedures have been performed in the U.S. during early clinical and initial commercial use. The addressable U.S. population remains substantial, with an estimated ~35 million adults potentially eligible for treatment. Recent reimbursement milestones, including Medicare’s Coverage with Evidence Development in October 2025 and Japan’s national insurance coverage for Paradise in March 2026, have helped transition the field from clinical trials into an emerging reimbursed commercial market.

 

The Addressable Market Is Constrained by Clinical Eligibility, Referral Pathways, and Reimbursement

Hypertension represents a very large patient pool, but only a small fraction are eligible for renal denervation. In the U.S. alone, the CDC estimates 119.9 million adults (48.1%) have hypertension, contributing to 680,179 deaths in 2024. Prevalence rises sharply with age, reaching 71.6% in adults over 60.

However, treatment control remains low. Only 20.7% of hypertensive patients achieve blood pressure below 130/80 mmHg, despite 51.2% being on medication. This gap reflects poor adherence, insufficient treatment escalation, and undiagnosed secondary causes, meaning most patients are not immediate candidates for device-based intervention.

As a result, renal denervation is limited to a carefully selected subgroup with confirmed, persistent uncontrolled hypertension after optimized medical therapy and specialist evaluation. Adoption is therefore concentrated in advanced hospital systems with integrated cardiology, nephrology, and imaging capabilities that can consistently identify and refer eligible patients.

 

Technology Segmentation: Radiofrequency Leads, but Ultrasound and Chemical Systems Grow Faster

Radiofrequency renal denervation led the market with a 54.0% share in 2025, generating about USD 0.3132 billion and projected to reach USD 0.7546 billion by 2032 (CAGR 13.39%). Its dominance is driven by Medtronic’s Symplicity Spyral system, which benefits from broad regulatory approvals in the U.S., China, and Japan, as well as strong hospital and physician training networks. The multielectrode catheter design also aligns well with standard interventional workflows, supporting easier adoption in catheter labs.

Ultrasound-based systems held 42.0% share in 2025 (USD 0.2436 billion) and are expected to grow faster to USD 0.7084 billion by 2032 (CAGR 16.47%). Growth is led by ReCor Medical’s Paradise system, which has FDA approval, Medicare evidence-based coverage access, and reimbursement in Japan. Its circumferential ultrasound delivery with cooling technology offers more uniform nerve ablation, while Otsuka’s ownership strengthens its reach in hypertension-focused markets.

Chemical renal denervation remains a small but fast-growing segment at 4.0% share in 2025 (USD 0.0232 billion), projected to reach USD 0.0770 billion by 2032 (CAGR 18.69%). It is still in early development, with investigational alcohol-based systems aiming to simplify procedures and reduce reliance on capital equipment. However, adoption remains limited due to the need for stronger clinical evidence on safety, durability, and delivery precision, despite ongoing regulatory interest such as NICE’s 2025 review.

 

Product Segmentation: Catheters Capture Most Revenue Through Procedure-Linked Demand

Renal denervation catheters dominated the product market with a 58.0% share in 2025, generating USD 0.3364 billion, and are projected to reach USD 0.9856 billion by 2032 (CAGR 16.60%). Growth is driven by their role as single-use, procedure-linked devices, meaning every treatment directly generates catheter demand. Expansion is further supported by CMS reimbursement clarity, including HCPCS codes C1735 and C1736 for radiofrequency and ultrasound systems, which improves hospital adoption and budgeting.

Energy generators and consoles held a 29.0% share in 2025 (USD 0.1682 billion) and are expected to reach USD 0.3388 billion by 2032 (CAGR 10.52%). Growth is slower as these are reusable capital devices, typically placed in hospitals during program launch phases, with manufacturers often using leasing or bundled supply models to encourage adoption.

Accessories and consumables accounted for 13.0% in 2025 (USD 0.0754 billion) and are projected to reach USD 0.2156 billion by 2032 (CAGR 16.19%), supported by ongoing procedural needs such as guidewires, introducers, tubing, and other supporting components.

Accessories benefit from the same procedure-volume growth as catheters. Their revenue also increases as hospitals standardize renal denervation kits, reduce preparation variability, and establish repeatable interventional workflows.

 

Mixed Clinical Evidence Reinforces Selective and Specialist-Driven Adoption

Clinical trials have shown meaningful blood-pressure reductions, but outcomes vary by technology, medication status, trial design, patient population, and measurement method. In RADIANCE-HTN SOLO, ultrasound renal denervation reduced daytime ambulatory systolic blood pressure by 8.5 mmHg after two months, compared with 2.2 mmHg in the sham group. RADIANCE II produced a similar 6.3 mmHg difference between treatment and control groups.

The resistant-hypertension RADIANCE-HTN TRIO study reported a 4.5 mmHg between-group reduction, although its prespecified comparison did not reach statistical significance. Medtronic’s SPYRAL HTN-OFF MED pivotal study showed greater reductions in ambulatory and office systolic pressure than sham treatment. The SPYRAL HTN-ON MED study produced a smaller difference in 24-hour pressure and did not meet its primary superiority endpoint at six months.

CMS reviewed seven randomized trials involving 1,465 patients and concluded that renal denervation had a generally favorable safety profile but mixed effectiveness across medication conditions and study designs. These results support selected use rather than broad replacement of pharmaceutical treatment.

The American Heart Association reports durability for up to 36 months in available studies, but responses remain variable and average blood-pressure reductions are generally modest. Higher baseline blood pressure is one of the most consistent predictors of response. Manufacturers must therefore support patient-selection protocols rather than relying only on technical product differentiation.

 

Guidelines Keep Renal Denervation Inside Specialist Hypertension Care

The 2024 European Society of Cardiology guideline formally recognized catheter-based renal denervation for selected patients with resistant hypertension whose blood pressure remains uncontrolled despite a three-drug combination that includes a thiazide or thiazide-like diuretic. The procedure should follow shared decision-making and multidisciplinary assessment at a medium- or high-volume center.

Renal denervation is not recommended as a first-line intervention or for patients with an estimated glomerular filtration rate below 40 mL/min/1.73 m² or untreated secondary hypertension. These restrictions direct procedures toward experienced institutions and reduce inappropriate use.

The 2025 American hypertension guideline also recognizes renal denervation for selected resistant-hypertension patients while emphasizing accurate blood-pressure measurement, home monitoring, medication adherence, and team-based care. The American Heart Association identifies sustained uncontrolled hypertension, medication intolerance, adherence difficulty, and high cardiovascular risk as relevant selection factors.

NICE remains more restrictive in the United Kingdom. Its recommendations permit renal sympathetic denervation under special arrangements for clinical governance, consent, audit, or research. The position limits rapid NHS adoption and increases the importance of registry evidence, long-term follow-up, and structured center oversight.

 

End-User Segmentation: Hospitals Retain Scale While ASCs Record the Fastest Growth

Hospitals dominated the renal denervation devices market with an 80.0% share in 2025, generating USD 0.4640 billion and projected to reach USD 1.1858 billion by 2032 (CAGR 14.34%). Their leadership is driven by the need for catheter labs, imaging, trained interventional teams, and multidisciplinary hypertension care, while Medicare’s Coverage with Evidence Development further concentrates procedures in hospital-based, study-capable centers.

Ambulatory surgical centers (ASCs) held a 10.0% share in 2025 (USD 0.0580 billion) and are expected to grow fastest at a 19.36% CAGR, reaching USD 0.2002 billion by 2032. Growth is supported by lower procedural costs and shorter stays, but expansion depends on payer approval, patient selection, and clinical infrastructure, meaning adoption will initially remain limited to select cases.

Specialty cardiology and hypertension clinics also accounted for a 10.0% share in 2025 (USD 0.0580 billion), projected to reach USD 0.1540 billion by 2032 (CAGR 14.97%). While they typically do not perform procedures, they play a key role in identifying eligible patients, confirming resistant hypertension, and driving referrals, making them critical to procedure volume growth.

 

Medicare Coverage Turns Evidence Collection into a Commercial Requirement

CMS issued its final national coverage decision on October 28, 2025, covering FDA-approved radiofrequency and ultrasound renal denervation under Coverage with Evidence Development. Eligible procedures must follow FDA-authorized indications and CMS requirements for patients, physicians, facilities, and approved studies.

CMS requires documented uncontrolled hypertension of at least 140 mmHg systolic and above 90 mmHg diastolic despite active clinical management. Medtronic’s SPYRAL CARE study was approved on October 30, 2025, while ReCor’s RADIANCE CED study received approval on November 21, 2025.

The coverage structure reduces the risk of hospitals establishing completely unfunded programs, but it concentrates early volume in centers able to support screening, study enrollment, data submission, claims management, and long-term follow-up. Evidence generation is therefore part of the commercial delivery model rather than a separate research activity.

 

Regional Market Direction: North America Leads While Asia-Pacific Expands

North America held the largest share at 36.0% in 2025, valued at USD 0.2088 billion, and is projected to reach USD 0.6006 billion by 2032 (CAGR 16.29%). Growth is driven by FDA-approved systems, Medicare coverage, and a large patient base, with about 119.9 million U.S. adults affected by hypertension and only 20.7% achieving control (CDC/NCHS). Adoption is mainly concentrated in specialist hospitals and advanced outpatient centers.

Europe accounted for 32.0% of the market in 2025 (USD 0.1856 billion) and is expected to reach USD 0.4312 billion by 2032 (CAGR 12.80%). Around 45% of adults in Europe have hypertension (ESC), and England alone reports a 15.2% prevalence across 6,188 primary care practices. However, uneven reimbursement and NICE restrictions limit faster uptake despite strong clinical experience.

Asia-Pacific held 24.0% share in 2025 (USD 0.1392 billion) and is projected to grow to USD 0.3850 billion by 2032 (CAGR 15.64%). Growth is supported by approvals in China (NMPA approval of Symplicity Spyral in 2024) and Japan (approval of Paradise and Symplicity Spyral in 2025, with Paradise reimbursed in 2026). China has about 270 million hypertensive patients with only 13.8% control (WHO), making it a major demand base.

Latin America represented 5.0% of the market in 2025 (USD 0.0290 billion) and is expected to reach USD 0.0770 billion by 2032 (CAGR 14.97%). Growth is mainly driven by private hospitals and urban cardiovascular centers with access to catheter-based procedures.

The Middle East and Africa held 3.0% share in 2025 (USD 0.0174 billion) and is projected to reach USD 0.0462 billion by 2032 (CAGR 14.97%). Expansion is concentrated in Gulf-region tertiary hospitals, while limited reimbursement, specialist availability, and infrastructure continue to restrict wider adoption.

 

Competitive Landscape: Evidence Networks Matter More Than Catheter Specifications

Medtronic and ReCor Medical currently lead the approved renal denervation market. Medtronic holds a strong position with its Symplicity Spyral radiofrequency system, supported by global cardiovascular reach, established catheter-lab networks, and approvals in the U.S., China, and Japan, along with CMS-backed evidence programs. This scale helps maintain radiofrequency’s 54.0% market share, though long-term growth depends on proving consistent real-world outcomes in broader patient groups.

ReCor Medical, owned by Otsuka, competes with its Paradise ultrasound system, which benefits from FDA approval, Japanese reimbursement, and CMS-supported clinical evidence programs. These factors are driving ultrasound’s faster projected growth at a 16.47% CAGR, supported by expanding international adoption and strong hypertension-focused commercialization through Otsuka’s network.

Boston Scientific has also entered the space through its acquisition of SoniVie, developer of the investigational TIVUS ultrasound platform, in a deal worth about USD 360 million upfront plus up to USD 180 million in milestones. Although still not commercially cleared, the company could leverage its global interventional cardiology infrastructure to become a future competitor.

Chemical renal denervation remains early-stage but is the fastest-growing segment, projected at an 18.69% CAGR from a small base of USD 0.0232 billion. Its success will depend on proving safety, procedural simplicity, and reliable nerve ablation.

Overall, competition is shifting beyond device design toward building strong referral networks, physician training, reimbursement access, and real-world evidence. Companies that streamline the path from diagnosis to reimbursed treatment are likely to capture the most value.

 

New Drug Options Raise the Threshold for Procedural Adoption

Renal denervation is entering the market while pharmaceutical treatment is also advancing. The FDA approved AstraZeneca’s Baxfendy, or baxdrostat, in May 2026 for adults whose hypertension remains inadequately controlled with other therapies. The prescribing information requires potassium, sodium, and renal-function monitoring because of hyperkalemia and hyponatremia risks.

Baxdrostat expands the number of medical options that may be considered before procedural referral. Renal denervation manufacturers must therefore position their systems around continuous treatment effect, reduced dependence on daily adherence, and suitability for selected patients with persistent uncontrolled pressure, treatment intolerance, or high medication burden. Current approvals and guidelines position the procedure as an adjunct rather than a universal replacement for antihypertensive medication.

 

Analyst Perspective: Renal Denervation Is Becoming a Specialized Care Pathway

Renal denervation is now supported by strong clinical validation, regulatory approvals, and expanding reimbursement, including FDA approvals for Medtronic and ReCor systems, Medicare coverage in the U.S., and approvals in Japan and China. These factors underpin market growth from USD 0.58 billion in 2025 to USD 1.54 billion by 2032.

Radiofrequency systems currently lead the market, but ultrasound and emerging chemical approaches are growing faster. Catheters remain the main revenue driver due to repeat use per procedure, while hospitals dominate adoption and ambulatory surgical centers are expected to grow fastest as procedures become more standardized.

North America leads due to FDA approvals and Medicare support, while Asia-Pacific is expanding on the back of large patient volumes in China and reimbursement progress in Japan. Europe is growing more slowly due to varied national reimbursement systems.

Commercial success depends on a clear care pathway: uncontrolled hypertension → specialist evaluation → referral → reimbursed procedure → recurring device use and follow-up data generation.

Medtronic and ReCor currently lead the market, while Boston Scientific is emerging as a key competitor through pipeline acquisitions. Overall, renal denervation is evolving into a structured hypertension treatment service, where companies that integrate diagnosis, referral networks, reimbursement, and long-term outcomes will capture the most value.

 

Renal Denervation Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 0.58 Billion
Revenue Forecast in 2032	USD 1.54 Billion
Overall Growth Rate	CAGR of 15.0% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Technology, By Product, By End User, By Geography
By Technology	Radiofrequency-Based Renal Denervation, Ultrasound-Based Renal Denervation, Chemical-Based Renal Denervation
By Product	Renal Denervation Catheters, Energy Generators and Consoles, Accessories and Consumables
By End User	Hospitals, Ambulatory Surgical Centers, Specialty Cardiology and Hypertension Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of uncontrolled and resistant hypertension, regulatory approval of radiofrequency and ultrasound systems, expanding reimbursement coverage, specialist referral pathways, physician training, and growing adoption of minimally invasive hypertension procedures
Customization Option	Available upon request